Showing results (321-330 of 366) with videos related to

Sort By:
Pageof 37
Molecular Cancer Therapeutics|April 7, 2016
Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial EvaluationJoo Ern Ang, Rupinder Pandher, Joo Chew Ang, et al.
Molecular Oncology|October 25, 2017
Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitorSteven R Whittaker, Clare Barlow, Mathew P Martin, et al.
Molecular Cancer Therapeutics|June 23, 2017
Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic MelanomaJoo Ern Ang, Akos Pal, Yasmin J Asad, et al.
Cell Reports. Medicine|February 1, 2021
Targeted brachyury degradation disrupts a highly specific autoregulatory program controlling chordoma cell identityHadley E Sheppard, Alessandra Dall'Agnese, Woojun D Park, et al.
Journal of Medicinal Chemistry|October 10, 2012
Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemiaVassilios Bavetsias, Simon Crumpler, Chongbo Sun, et al.
ACS Medicinal Chemistry Letters|June 22, 2016
2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with Potent, Selective Affinity for CDK8/19Aurélie Mallinger, Kai Schiemann, Christian Rink, et al.
Cancer Research|May 20, 2016
Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer CellsRoberta Ferraldeschi, Jonathan Welti, Marissa V Powers, et al.
Scientific Reports|October 7, 2016
A fragment-based approach applied to a highly flexible target: Insights and challenges towards the inhibition of HSP70 isoformsAlan M Jones, Isaac M Westwood, James D Osborne, et al.
Cancer Research|March 3, 2007
In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitorsSwee Y Sharp, Kathy Boxall, Martin Rowlands, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2009
EGFRvIII deletion mutations in pediatric high-grade glioma and response to targeted therapy in pediatric glioma cell linesDorine A Bax, Nathalie Gaspar, Suzanne E Little, et al.
Pageof 37